SCHEDULE C
TO THE EXCLUSIVE LICENSE AGREEMENT
LICENSED TRADEMARKS
Reference: Exclusive License Agreement dated October 2, 2023 (the "Agreement"), effective as of October 20, 2023 (the "Effective Date"), by and between Penterra Pharmaceuticals Corp., a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 200 Riverview Center Drive, Suite 1400, Wilmington, Delaware 19801 ("Licensor"), and Meridian Bio Therapeutics Limited, a limited company organized and existing under the laws of Hong Kong, having its registered office at Level 28, Two International Finance Centre, 8 Finance Street, Central, Hong Kong ("Licensee").
Capitalized terms used but not defined in this Schedule C shall have the meanings ascribed to such terms in the Agreement. In the event of any conflict between the provisions of this Schedule C and the body of the Agreement, the provisions of the Agreement shall control, except to the extent that this Schedule C expressly provides otherwise with respect to the identification or description of the Licensed Trademarks.
1. Overview and Scope
This Schedule C sets forth the Licensed Trademarks as defined in Article 1 of the Agreement. The purpose of this Schedule C is to identify, with specificity, all trademark registrations, pending trademark applications, and common law trademark rights that constitute the Licensed Trademarks and that are subject to the exclusive license granted to Licensee under the Agreement.
The Licensed Trademarks consist of all trademark registrations, applications for trademark registration, and common law trademark rights owned or controlled by Licensor relating to the proposed trade name "PENTECLAR" for the Licensed Product (compound code PPC-4187, proposed International Nonproprietary Name: Penteracitinib) in the Licensed Territory, as well as the corresponding United States federal trademark registration maintained by Licensor as part of the global PENTECLAR brand and listed herein for reference purposes only.
Licensee is granted an exclusive license to use the Licensed Trademarks solely within the Territory (as defined in Schedule D to the Agreement) in connection with the development, manufacture, and commercialization of the Licensed Product, subject to and in accordance with the terms and conditions of the Trademark License Agreement executed concurrently with the Agreement on October 2, 2023. For the avoidance of doubt, Licensee's rights to use the Licensed Trademarks are coextensive with, and limited to, the scope of the exclusive license granted under Article 2 of the Agreement, and Licensee shall not use or authorize the use of the Licensed Trademarks in any jurisdiction outside the Territory or for any product other than the Licensed Product.
The trademark registrations and applications listed in Section 2 below represent the Licensed Trademark portfolio as of the Effective Date. This Schedule C shall be updated from time to time in accordance with Section 6 hereof to reflect new filings, registrations, changes in status, or other developments in the Licensed Trademark portfolio.
2. Table of Registered and Pending Trademarks
Set forth below is a comprehensive listing of all trademark registrations and pending applications that constitute the Licensed Trademarks as of the Effective Date, organized by country or jurisdiction. Each entry includes the mark, the relevant filing or registration authority, application and registration numbers (where available), filing and registration dates (where applicable), current prosecution status, applicable international classification(s), and the owner of record.
2.1 United States of America (Reference Registration)
The following United States trademark registration is included in this Schedule C for reference purposes only. The United States of America is part of the Retained Territory, and the inclusion of this registration does not convey, and shall not be construed to convey, any rights to Licensee in the United States or in any jurisdiction outside the Territory.
Note: This U.S. registration (Reg. No. 6,789,012) is listed solely for reference purposes to document the existence of the global PENTECLAR brand. Licensee has no rights to use the PENTECLAR mark in the United States under the Agreement. Licensor retains all rights, title, and interest in and to this registration and all goodwill associated therewith. A Section 8 Declaration of Continued Use is due on or before January 10, 2029, and a Section 9 Renewal Application is due on or before January 10, 2033. Maintenance of this registration shall be the sole responsibility of Licensor.
2.2 Hong Kong Special Administrative Region
2.3 People's Republic of China (Mainland)
Note: The Chinese-character equivalent mark 朋特克 has been filed concurrently with the English-language PENTECLAR mark in Mainland China to secure protection of the phonetic transliteration of the brand name in the local language. Both the English-language mark and the Chinese-character mark are included within the Licensed Trademarks for purposes of this Schedule C and the Agreement.
2.4 Macau Special Administrative Region
2.5 Japan.
Note: The katakana equivalent mark ペンテクラー has been filed concurrently with the English-language PENTECLAR mark in Japan to secure protection of the phonetic transliteration of the brand name in the Japanese language. Both the English-language mark and the katakana mark are included within the Licensed Trademarks for purposes of this Schedule C and the Agreement.
2.6 Republic of Korea
2.7 Australia.
2.8 New Zealand
2.9 Republic of Singapore
2.10 Kingdom of Thailand
2.11 Malaysia.
2.12 Republic of Indonesia
2.13 Republic of the Philippines
2.14 Socialist Republic of Vietnam
2.15 Taiwan.
3. Description of the Mark
The following description applies to the Licensed Trademarks identified in Section 2 above, across all jurisdictions:
(a) Word Mark. The Licensed Trademarks consist of the word mark PENTECLAR in standard characters. Where local-language equivalents have been filed (including, without limitation, the Chinese-character mark 朋特克 in the People's Republic of China and the katakana mark ペンテクラー in Japan), such local-language equivalents are also included within the Licensed Trademarks.
(b) Design Elements. No design element, logo, or stylized representation forms part of the Licensed Trademarks as of the Effective Date. The mark is filed and registered as a standard character mark (also referred to as a "word mark") in all listed jurisdictions, affording protection to the word "PENTECLAR" regardless of the font, style, size, or color in which it is displayed.
(c) Goods Description (International Class 5). The goods covered by the Licensed Trademarks in all jurisdictions are as follows:
Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof.
(d) Dosage Forms. As of the Effective Date, the Licensed Product is being developed in two dosage strengths: 25 mg film-coated tablets and 50 mg film-coated tablets. The goods description set forth in subsection (c) above is intended to encompass both dosage strengths and any additional dosage forms or strengths that may be developed for the Licensed Product during the term of the Agreement, subject to any necessary amendments to the trademark registrations and applications.
(e) Proposed International Nonproprietary Name (INN). The proposed INN for the Licensed Product is Penteracitinib. The INN is not part of the Licensed Trademarks and is not subject to the exclusive license granted under the Agreement, it being understood that INNs are nonproprietary names designated by the World Health Organization and may not be appropriated as trademarks.
(f) Compound Code. The internal compound code assigned by Licensor to the Licensed Product is PPC-4187. The compound code is used for internal identification and regulatory filing purposes and does not form part of the Licensed Trademarks.
4. Domain Names
The following domain name registrations related to the PENTECLAR mark are held by Licensor as of the Effective Date and are included in or associated with the Licensed Trademarks to the extent relevant to the Territory. Licensee shall have the right to use or direct the use of the Territory-specific domain names listed below in connection with the commercialization of the Licensed Product in the Territory, subject to the terms and conditions of the Agreement and the Trademark License Agreement:
Note: The global domain penteclar.com is retained by Licensor and is not included within the Licensed Trademarks or the scope of the license granted to Licensee under the Agreement. Licensor shall maintain registration and control of penteclar.com at its own cost and shall ensure that any content hosted at penteclar.com does not interfere with Licensee's exclusive rights in the Territory. The parties shall cooperate in good faith to ensure that penteclar.com contains appropriate geographic routing or disclaimers to direct Territory-based users to Licensee's Territory-specific websites, as further described in the Commercialization Plan to be agreed upon by the parties pursuant to Article 5 of the Agreement.
Licensor shall be responsible for the timely renewal of all domain name registrations listed in this Section 4 during the term of the Agreement. Licensee shall reimburse Licensor for the reasonable, documented out-of-pocket costs of such renewals within thirty (30) days of receipt of an invoice therefor.
5. Obligations Regarding Licensed Trademarks
5.1 Prosecution and Maintenance
Licensor shall maintain ownership of, and shall be responsible for the prosecution and maintenance of, all Licensed Trademark applications and registrations listed in this Schedule C during the term of the Agreement. Without limiting the generality of the foregoing, Licensor shall:
(a) prosecute to registration, at Licensor's own cost and expense, all pending trademark applications listed in Section 2 of this Schedule C, including responding to any office actions, examiner objections, or third-party oppositions that may arise during the prosecution process;
(b) pay all official fees, annuities, renewal fees, and other charges required to maintain the Licensed Trademark registrations in full force and effect throughout the term of the Agreement;
(c) keep Licensee reasonably informed of the status of all pending applications and registered trademarks listed in this Schedule C, including by providing written notice to Licensee within fifteen (15) business days of (i) the issuance of any registration certificate, (ii) the receipt of any office action or examiner's objection, (iii) the filing or receipt of any opposition or cancellation proceeding, or (iv) any other material development affecting the validity or enforceability of any Licensed Trademark;
(d) not abandon, withdraw, or allow to lapse any Licensed Trademark registration or application listed in this Schedule C without the prior written consent of Licensee, such consent not to be unreasonably withheld, conditioned, or delayed; and
(e) coordinate with Licensee through the Joint Patent Committee ("JPC"), consisting of two (2) representatives designated by each party, regarding all material decisions relating to trademark prosecution, maintenance, and enforcement strategy in the Territory, as further set forth in Article 7 of the Agreement. The JPC shall meet no less frequently than once per calendar quarter, or more frequently as circumstances may require, to review the status of the Licensed Trademark portfolio and to discuss and coordinate any enforcement actions or defensive measures that may be necessary to protect the Licensed Trademarks in the Territory.
5.2 Recordation of License
Licensee shall, at its own cost and expense and with the reasonable cooperation of Licensor, record the trademark license granted under the Agreement in each jurisdiction within the Territory where such recordation is required by applicable law or where the parties determine, through the JPC, that such recordation is advisable for the protection of Licensee's interests or the enforceability of the license. Licensor shall promptly execute and deliver to Licensee all documents, powers of attorney, declarations, and other instruments reasonably required to effect such recordation. Licensee shall provide Licensor with copies of all recordation certificates and confirmations promptly upon receipt thereof.
5.3 Quality Control
Use of the PENTECLAR mark and all other Licensed Trademarks by Licensee, its Affiliates, and its sublicensees (to the extent sublicensing is permitted under the Agreement) is subject to the quality control provisions set forth in the Trademark License Agreement executed concurrently with the Agreement on October 2, 2023. Without limiting the terms of the Trademark License Agreement, Licensee acknowledges and agrees that:
(a) all products and services offered by Licensee under the Licensed Trademarks shall meet or exceed the quality standards established by Licensor and communicated to Licensee from time to time;
(b) Licensor shall have the right, upon reasonable prior notice and during normal business hours, to inspect and review samples of products bearing the Licensed Trademarks and to audit Licensee's quality control procedures to ensure compliance with the applicable quality standards; and
(c) all goodwill arising from Licensee's use of the Licensed Trademarks shall inure to the benefit of Licensor as the owner of the Licensed Trademarks.
5.4 New Filings
If, at any time during the term of the Agreement, Licensee identifies any additional jurisdictions within the Territory where trademark protection for PENTECLAR (or any local-language equivalent thereof) is advisable but where no application has been filed as of the Effective Date, Licensee shall promptly notify Licensor in writing, and the parties shall coordinate through the JPC regarding the appropriate filing strategy, including the scope of goods to be covered, the filing timeline, and the allocation of costs associated with such new filings. Unless otherwise agreed in writing by the parties, Licensor shall be responsible for filing and prosecuting any new trademark applications identified pursuant to this Section 5.4, and the costs of such filings shall be allocated as determined by the JPC in accordance with the cost-sharing principles set forth in Article 8 of the Agreement. Any trademark registrations or applications filed pursuant to this Section 5.4 shall be automatically added to this Schedule C upon written notice from Licensor to Licensee confirming the relevant filing details.
6. Amendments to This Schedule
This Schedule C may be amended from time to time by the mutual written agreement of the parties, executed by authorized representatives of both Licensor and Licensee, to:
(a) add newly filed trademark applications or newly issued trademark registrations relating to the PENTECLAR mark (or any local-language equivalent thereof) in the Territory;
(b) update application numbers, registration numbers, filing dates, registration dates, and prosecution status information for any of the trademarks listed in Section 2 hereof;
(c) add or remove domain name registrations listed in Section 4 hereof;
(d) reflect changes in the owner of record resulting from corporate restructurings, assignments, or other transactions, provided that any such change is consistent with the terms of the Agreement; or
(e) otherwise reflect changes in the Licensed Trademark portfolio as the parties may agree.
Notwithstanding the foregoing, any trademark registrations or applications acquired by or filed by Licensor after the Effective Date that relate to the PENTECLAR mark (including any local-language equivalents or variations thereof) in any country or jurisdiction within the Territory shall be automatically deemed added to this Schedule C, and shall constitute Licensed Trademarks for all purposes of the Agreement, upon written notice from Licensor to Licensee setting forth the relevant filing or registration details. Such written notice shall be deemed to amend this Schedule C without the need for a formal amendment executed by both parties, provided that Licensee shall have the right to object to the inclusion of any such trademark within thirty (30) days of receipt of such notice, in which case the parties shall resolve the matter through the JPC.
The parties shall use commercially reasonable efforts to update this Schedule C no less frequently than once every six (6) months to ensure that it accurately reflects the current status of the Licensed Trademark portfolio.
7. Disclaimers
(a) Licensor makes no representation or warranty that any pending trademark application listed in Section 2 of this Schedule C will proceed to registration, will be granted without amendment or limitation to the goods description, or will be free from opposition, cancellation, or other challenge by third parties. The representations and warranties of Licensor regarding the Licensed Trademarks, including representations and warranties as to ownership, validity, enforceability, and non-infringement, are set forth solely in Article 10 of the Agreement, and nothing in this Schedule C shall be construed to expand, modify, or supplement such representations and warranties.
(b) The inclusion of the United States trademark registration (Registration No. 6,789,012) in Section 2.1 of this Schedule C is for reference purposes only and is intended solely to document the existence and status of the U.S. PENTECLAR registration as part of Licensor's global brand portfolio. Such inclusion does not convey, and shall not be construed to convey, any rights to Licensee in the United States of America or in any other jurisdiction outside the Territory as defined in Schedule D to the Agreement. Licensor retains all rights, title, and interest in and to the U.S. registration and all goodwill associated therewith.
(c) Nothing in this Schedule C shall be construed to limit or modify the terms of the Agreement or the Trademark License Agreement with respect to the scope of the license, the obligations of the parties, or the rights of Licensor as the owner of the Licensed Trademarks.
[Remainder of this page intentionally left blank. Signature page follows.]
SCHEDULE C — LICENSED TRADEMARKS
SIGNATURE PAGE
IN WITNESS WHEREOF, the undersigned authorized representatives of the parties have acknowledged and agreed to this Schedule C as of the Effective Date.
LICENSOR:
PENTERRA PHARMACEUTICALS CORP.
By: ________
Name: Dr. Steven R. Calloway
Title: Chief Executive Officer
Date: ________
LICENSEE:
MERIDIAN BIO THERAPEUTICS LIMITED
By: ________
Name: James C.W. Leung
Title: Managing Director
Date: ________
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | United States of America |
| Filing Authority | United States Patent and Trademark Office (USPTO) |
| Application No. | 90/654,218 |
| Filing Date | March 14, 2022 |
| Registration No. | 6,789,012 |
| Registration Date | January 10, 2023 |
| Status | Registered |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective JAK1 inhibitor for the treatment of atopic dermatitis |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Hong Kong Special Administrative Region, People's Republic of China |
| Filing Authority | Trade Marks Registry, intellectual Property Department, Hong Kong SAR |
| Application No. | 306127483 |
| Filing Date | April 3, 2023 |
| Registration No. | 306127483 |
| Registration Date | September 15, 2023 |
| Status | Registered |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | People's Republic of China (excluding Hong Kong SAR and Macau SAR, which are listed separately in Sections 2.2 and 2.4, respectively) |
| Filing Authority | China National intellectual Property Administration (CNIPA) |
| Application No. | 69832451 |
| Filing Date | April 5, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (substantive examination stage) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | 朋特克 (Chinese-character equivalent) |
| Mark Type | Word mark (Chinese characters) |
| Country / Jurisdiction | People's Republic of China (excluding Hong Kong SAR and Macau SAR) |
| Filing Authority | China National intellectual Property Administration (CNIPA) |
| Application No. | 69832467 |
| Filing Date | April 5, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (substantive examination stage) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Macau Special Administrative Region, People's Republic of China |
| Filing Authority | Economic and Technological Development Bureau (DSEDT), Macau SAR |
| Application No. | N/076421 |
| Filing Date | May 18, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Japan |
| Filing Authority | Japan Patent Office (JPO) |
| Application No. | 2023-048712 |
| Filing Date | April 10, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (examination requested) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | ペンテクラー (katakana equivalent) |
| Mark Type | Word mark (katakana characters) |
| Country / Jurisdiction | Japan |
| Filing Authority | Japan Patent Office (JPO) |
| Application No. | 2023-048713 |
| Filing Date | April 10, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (examination requested) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Republic of Korea |
| Filing Authority | Korean intellectual Property Office (KIPO) |
| Application No. | 40-2023-0062194 |
| Filing Date | April 12, 2023 |
| Registration No. | 40-1987231 |
| Registration Date | September 28, 2023 |
| Status | Registered |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Commonwealth of Australia |
| Filing Authority | IP Australia |
| Application No. | 2234891 |
| Filing Date | April 7, 2023 |
| Registration No. | 2234891 |
| Registration Date | October 3, 2023 |
| Status | Registered |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | New Zealand |
| Filing Authority | Intellectual Property Office of New Zealand (IPONZ) |
| Application No. | 1198247 |
| Filing Date | April 14, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (accepted; awaiting registration) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Republic of Singapore |
| Filing Authority | Intellectual Property Office of Singapore (IPOS) |
| Application No. | 40202309184V |
| Filing Date | April 18, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (examination stage) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Kingdom of Thailand |
| Filing Authority | Department of intellectual Property (DIP), Ministry of Commerce |
| Application No. | 230104563 |
| Filing Date | April 20, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (examination stage) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Malaysia |
| Filing Authority | Intellectual Property Corporation of Malaysia (MyIPO) |
| Application No. | TM2023014782 |
| Filing Date | April 22, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (examination stage) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Republic of Indonesia |
| Filing Authority | Directorate General of intellectual Property (DGIP), Ministry of Law and Human Rights |
| Application No. | DID2023029841 |
| Filing Date | April 25, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (formalities examination stage) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Republic of the Philippines |
| Filing Authority | Intellectual Property Office of the Philippines (IPOPHL) |
| Application No. | 4-2023-500642 |
| Filing Date | April 26, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (substantive examination stage) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Socialist Republic of Vietnam |
| Filing Authority | National Office of intellectual Property (NOIP), Ministry of Science and Technology |
| Application No. | 4-2023-18472 |
| Filing Date | April 28, 2023 |
| Registration No. | — |
| Registration Date | — |
| Status | Application pending (formalities examination stage) |
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof |
| Owner of Record | Penterra Pharmaceuticals Corp. |
| Item | Detail |
| Mark | PENTECLAR |
| Mark Type | Standard character mark (word mark) |
| Country / Jurisdiction | Taiwan |
| Filing Authority | Taiwan intellectual Property Office (TIPO), Ministry of Economic Affairs |
| Application No. | 112028194 |
| Filing Date | April 17, 2023 |
| Registration No. | — |
| Registration Date | — | |||
| Status | Application pending (substantive examination stage) | |||
| International Class(es) | Class 5 — Pharmaceutical preparations, namely, a selective Janus kinase 1 (JAK1) inhibitor in oral tablet form for the treatment of moderate-to-severe atopic dermatitis in adults; active pharmaceutical ingredients used in the manufacture thereof | |||
| Owner of Record | Penterra Pharmaceuticals Corp. | |||
| Domain Name | Registrar | Registration Date | Expiration Date | Status |
| penteclar.cn | Beaumont & Co. | March 28, 2023 | March 28, 2025 | Active |
| penteclar.com.cn | Beaumont & Co. | March 28, 2023 | March 28, 2025 | Active |
| penteclar.jp | Harborview Enterprises | March 29, 2023 | March 29, 2025 | Active |
| penteclar.co.jp | Harborview Enterprises | March 29, 2023 | March 29, 2025 | Active |
| penteclar.com.au | Marlowe Enterprises | March 30, 2023 | March 30, 2025 | Active |
| penteclar.co.kr | Korea Internet & Security Agency | April 2, 2023 | April 2, 2025 | Active |
| penteclar.com.hk | Vireo Corporation | April 3, 2023 | April 3, 2025 | Active |
| penteclar.hk | Vireo Corporation | April 3, 2023 | April 3, 2025 | Active |
| penteclar.sg | Singapore Network Information Centre Pte. Ltd. | April 5, 2023 | April 5, 2025 | Active |
| penteclar.com.sg | Singapore Network Information Centre Pte. Ltd. | April 5, 2023 | April 5, 2025 | Active |
| penteclar.co.th | Thai Network Information Center Foundation | April 6, 2023 | April 6, 2025 | Active |
| penteclar.my | Meridian Holdings | April 8, 2023 | April 8, 2025 | Active |
| penteclar.co.id | Pengelola Nama Domain Internet Indonesia | April 10, 2023 | April 10, 2025 | Active |
| penteclar.ph | Quillon Enterprises | April 10, 2023 | April 10, 2025 | Active |
| penteclar.vn | Vietnam Internet Network Information Center | April 12, 2023 | April 12, 2025 | Active |
| penteclar.tw | Taiwan Network Information Center | April 14, 2023 | April 14, 2025 | Active |
| penteclar.co.nz | InternetNZ | April 14, 2023 | April 14, 2025 | Active |